Market Research Logo

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2018: Deal trends, players and financials

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2018: Deal trends, players and financials

The Global Cancer Monoclonal Antibody Partnering 2012-2018: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer monoclonal antibody partnering deals
Most active companies in cancer monoclonal antibody partnering
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer monoclonal antibody partnering contract documents
Top cancer monoclonal antibody deals by value

This report provides details of the latest Cancer monoclonal antibody agreements announced in the healthcare sectors.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human aAb

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all Cancer monoclonal antibody partnering deals announced since Jan 2012, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer monoclonal antibody dealmaking since 2012, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer monoclonal antibody deals since 2012. Deals are listed by headline value, signed by big pharma, most active Cancer monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of Cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2012, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2012. The chapter is organized by specific Cancer monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Cancer monoclonal antibody partnering company A-Z, deal type definitions and Cancer monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer monoclonal antibody partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer monoclonal antibody technologies and products.

Key benefits

Global Cancer Monoclonal Antibody Partnering Terms & Agreements provides the reader with the following key benefits:

In-depth understanding of cancer monoclonal antibody deal trends since 2012
Access to headline, upfront, milestone and royalty data
Access to the structure of cancer monoclonal antibody agreements with numerous real life case studies
Comprehensive access to over 360 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies
Identify most active companies in cancer monoclonal antibody partnering
Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spot the emerging companies in the cancer monoclonal antibody area

Report scope

Global Cancer Monoclonal Antibody Partnering Terms & Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.

Cancer Monoclonal Antibody Partnering Terms & Agreements includes:

Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2012
Analysis of cancer monoclonal antibody deal structure
Access to headline, upfront, milestone and royalty data
Access to over 360 cancer monoclonal antibody deal records
The leading cancer monoclonal antibody deals by value since 2012

In Cancer Monoclonal Antibody Partnering Terms & Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific oncology therapy target
Monoclonal antibody type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Monoclonal Antibody Partnering Terms & Agreements report provides comprehensive access to available deals and contract documents for over 360 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?


  • Executive Summary
  • Introduction
  • Trends in Cancer monoclonal antibody dealmaking
    • Introduction
    • Cancer monoclonal antibody partnering over the years
    • Most active Cancer monoclonal antibody dealmakers
    • Cancer monoclonal antibody partnering by deal type
    • Cancer monoclonal antibody partnering by therapy area
    • Deal terms for Cancer monoclonal antibody partnering
      • Cancer monoclonal antibody partnering headline values
        • Table Cancer monoclonal antibody deals with a headline value
      • Cancer monoclonal antibody deal upfront payments
        • Table Cancer monoclonal antibody deals with an upfront value
      • Cancer monoclonal antibody deal milestone payments
        • Table Cancer monoclonal antibody deals with a milestone value
      • Cancer monoclonal antibody royalty rates
        • Table Cancer monoclonal antibody deals with a royalty rate value
  • Leading Cancer monoclonal antibody deals
    • Introduction
    • Top Cancer monoclonal antibody deals by value
      • Table Top Cancer monoclonal antibody deals by value since 2010
  • Most active Cancer monoclonal antibody dealmakers
    • Introduction
    • Most active Cancer monoclonal antibody dealmakers
    • Most active Cancer monoclonal antibody partnering company profiles
      • Merck and Co
      • Bristol-Myers Squibb
      • Pfizer
      • Genentech
      • National Cancer Institute
      • Amgen
      • Eli Lilly
      • GlaxoSmithKline
      • Macrogenics
      • MedImmune
      • Merck KGaA
      • AstraZeneca
      • Seattle Genetics
      • Boehringer Ingelheim
      • Genmab
      • Novartis
      • Janssen Biotech
      • MD Anderson Cancer Center
      • Roche
      • Celgene
      • Actinium Pharmaceuticals
      • Apexigen
      • ImmunoGen
      • MorphoSys
      • OncoMed Pharmaceuticals
  • Cancer monoclonal antibody contracts dealmaking directory
    • Introduction
    • Cancer monoclonal antibody contracts dealmaking directory
  • Cancer monoclonal antibody dealmaking by technology type
    • Monoclonal antibodies
  • Partnering resource center
    • Online partnering
    • Partnering events
    • Further reading on dealmaking
  • Appendices
    • Cancer monoclonal antibody deals by company A-Z
      • 3SBio
      • 4-Antibody
      • 4D Pharma
      • A*STAR Agency for Science, Technology and Research
      • A*STAR Bioprocessing Technology Institute
      • A-CUBE
      • Abbott Laboratories
      • Abbvie
      • Abeome
      • Abpro
      • Abzena
      • Actinium Pharmaceuticals
      • Adaptimmune
      • Adaptive Biotechnologies
      • ADC Therapeutics
      • AdnaGen
      • Aduro BioTech
      • Advanced Accelerator Applications
      • Advantagene
      • Advaxis
      • Aeglea BioTherapeutics
      • Affimed Therapeutics
      • Affinita Biotech
      • Affitech
      • Affomix
      • AGC Biologics
      • Agence Nationale de Recherches sur le SIDA et les hepatitives virales
      • Agensys
      • Agenus Bio
      • AIMM Therapeutics
      • Alethia Biotherapeutics
      • Algeta
      • Alligator Bioscience
      • Altor BioScience
      • Alvogen
      • Ambrx
      • Amgen-Beta Pharmaceuticals
      • Amgen
      • Amgen Astellas BioPharma
      • Amneal Pharmaceuticals
      • Amorfix Life Sciences
      • AnaptysBio
      • Angiogene
      • Anthera Pharmaceuticals
      • Antigen Express
      • Antisoma
      • Antitope
      • Apceth
      • Apeiron Biologics
      • Aperion Biologics
      • Apexigen
      • Aragen Bioscience
      • Areva Med
      • ArGEN-X
      • Array Biopharma
      • Ascenion
      • Aslan Pharma
      • Astellas Pharma
      • Astex Pharmaceuticals
      • AstraZeneca
      • Atara Biotherapeutics
      • Athenex
      • Atlab Pharma
      • Australian Research Council
      • Auven Therapeutics
      • AVEO Oncology
      • Aytu BioScience
      • BAC
      • Baize Investments
      • Banook Central Imaging
      • Bavarian Nordic
      • Baxalta
      • Bayer
      • Bayer Healthcare
      • Bayer Schering Pharma
      • Baylor College
      • Baylor Research Institute
      • BeiGene
      • BerGenBio
      • Biametrics
      • BioAtla
      • Biocare Medical
      • Bioceros
      • BiocerOX Products
      • Biocnd
      • Biodesix
      • Biogen
      • BioInvent
      • Biolex
      • BiolineRX
      • Biologics
      • BioMarker Strategies
      • Biotech Investment
      • Biothera
      • BioWa
      • Bio Farma
      • BliNK Biomedical
      • BliNK Therapeutics
      • Boehringer Ingelheim
      • Brigham and Women's Hospital
      • Bristol-Myers Squibb
      • BZL Biologics
      • Caliber Biotherapeutics
      • California Institute for Regenerative Medicine
      • Calithera Biosciences
      • Cambridge Biomedical
      • Cancer Prevention and Research Institute of Texas
      • Cancer Research Institute
      • Cancer Research Technology
      • Cancer Research UK
      • Catalent Pharma Solutions
      • CBT Pharmaceuticals
      • CDI Laboratories
      • Cedars-Sinai Medical Center
      • Celgene
      • Celldex Therapeutics
      • Celltrion
      • Cell Signaling Technology
      • Centocor Ortho Biotech
      • Centre for Drug Research and Development (CDRD)
      • Cephalon Australia
      • Champions Oncology
      • Checkmate Pharmaceuticals
      • Chemo Sa Lugano
      • Children´s Oncology Group (COG)
      • Children's Cancer Research Institute (CCRI)
      • Chinese Academy of Sciences
      • Chiome Bioscience
      • Chugai Pharmaceutical
      • Cimym
      • City of Hope
      • City University of New York Center for Advanced Technology
      • CJSC Biocad
      • Clal Biotech
      • Clarity Pharmaceuticals
      • Clavis Pharma
      • Clinica Universidad Navarra
      • Clovis Oncology
      • CMC Biologics
      • Cobra Biologics
      • Coherus Biosciences
      • Compugen
      • Conkwest
      • Cormorant Pharmaceuticals
      • Corvus Pharmaceuticals
      • Cosmo Pharmaceuticals
      • CoStim Pharmaceuticals
      • Covagen
      • Covalab
      • Crescendo Biologics
      • Crown Bioscience
      • CSL
      • Cullinan Oncology
      • CureTech
      • Curie-Cancer
      • CytomX Therapeutics
      • Cytovance Biologics
      • Daiichi Sankyo
      • Dako
      • Dana-Farber Cancer Institute
      • Debiopharm
      • DNAtrix
      • Domainex
      • Dompe Farmaceutici
      • Dr. Reddy's Laboratories
      • DSM Pharmaceutical Products
      • Dyax
      • Dynavax Technologies
      • Eclipse Aesthetics
      • EFFECTOR Therapeutics
      • Eisai
      • Eleven Biotherapeutics
      • Eli Lilly
      • ElsaLys Biotech
      • EMD Millipore
      • EMD Serono
      • Emergent BioSolutions
      • Emory University
      • Enlyten Medical Technologies
      • Enumeral Biomedical
      • Enzo Biochem
      • EpiThany
      • Epitomics
      • Erasmus University Medical Center
      • Essex Bio-Technology
      • Eureka Therapeutic
      • Eurofarma
      • Eurogentec
      • European Union
      • EUSA Pharma
      • Eutilex
      • ExonHit Therapeutics
      • Expression Analysis
      • Facet Biotechnology
      • Faron Pharmaceuticals
      • Fate Therapeutics
      • Five Prime Therapeutics
      • Florida Biologix
      • Fluidigm
      • Forty Seven
      • Fred Hutchinson Cancer Research Center
      • Fresenius Biotech
      • Fundacio Clinic
      • Galena Biopharma
      • Gallus Biopharmaceuticals
      • GamaMabs Pharma
      • GC Pharma
      • Genentech
      • Genexine
      • Genmab
      • Genome Institute of Singapore
      • Genomic Health
      • Genor Biopharma
      • Gen Ilac
      • Georgetown University
      • Gilead Sciences
      • Gladstone Institutes
      • GlaxoSmithKline
      • Gliknik
      • Glycotope Biotechnology
      • Glythera
      • Goodwin Biotechnology
      • Gradalis
      • Gritstone Oncology
      • Groupe d'Etude des Lymphomes de l'Adulte (GELA)
      • GSK Clinical Imaging Centre
      • H-Immune
      • Halozyme Therapeutics
      • Harbour Biomed
      • Hawthorn Pharmaceuticals
      • Heidelberg Pharma
      • HemispheRx Biopharma
      • Henry M. Jackson Foundation
      • Heptares Therapeutics
      • Hikma Pharmaceuticals
      • Hoffmann La Roche
      • Hokkaido University
      • Hospira
      • Hubrecht Institute
      • Humanigen
      • Human BioMolecular Research Institute
      • Hummingbird Bioscience
      • I2 Pharmaceuticals
      • IBA Molecular Imaging
      • IBC Generium
      • IBio
      • IDD Biotech
      • Idera Pharmaceuticals
      • IDIS Pharma
      • Ildong Pharmaceutical
      • Illumina
      • Imab
      • ImaginAb
      • ImmuneXcite
      • Immune Design
      • Immune Pharmaceuticals
      • ImmunGene
      • ImmunoCellular Therapeutics
      • ImmunoChina Pharmaceuticals
      • Immunocore
      • ImmunoGen
      • Immunomedics
      • Immutep
      • Incyte
      • Infinity Pharmaceuticals
      • Innate Pharma
      • Innexus
      • InnoKeys
      • InnoMab
      • Innovent Biologics
      • Inserm
      • Inserm Transfert
      • Institute of Biophysics
      • Institut Gustave Roussy
      • Internal Revenue Service
      • Invenra
      • IONTAS
      • IO Biotech
      • Ipca Laboratories
      • ISA Pharmaceuticals
      • IsoTherapeutics
      • Israeli National Authority for Technological Innovation
      • Janssen Biotech
      • Janssen Pharmaceuticals
      • Janssen Pharmaceutica NV
      • Janssen Research & Development
      • Jantibody Therapeutics
      • Jazz Pharmaceuticals
      • JHL Biotech
      • Jiangsu Hengrui Medicine
      • Jinfiniti Biosciences
      • Johnson & Johnson
      • Johnson & Johnson Innovation
      • Johns Hopkins Medicine (JHM)
      • Johns Hopkins University
      • John Hopkins University School of Medicines
      • Jounce Therapeutics
      • Juno Therapeutics
      • Kadmon Pharmaceuticals
      • KellBenx
      • Kelun-Biotech Biopharmaceutical
      • Kite Pharma
      • Kocak Pharma
      • Kolltan Pharmaceuticals
      • Kymab
      • Kyowa Hakko Kirin
      • Kyowa Hakko Kogyo
      • Kyto Biopharma
      • Lab21
      • Laureate BioPharmaceuticals
      • Leap Therapeutics
      • Lee's Pharmaceutical
      • Leica Biosystems
      • LEO Pharma
      • Leukemia & Lymphoma Society
      • LFB Biotechnologies
      • LG Life Sciences
      • LifeArc
      • Life Technologies Corporation
      • Ligacept
      • Lonza
      • Lpath
      • Ludwig Institute for Cancer Research
      • Lupagen
      • MabCure
      • Mabion
      • MabVax Therapeutics
      • MAbXience
      • MAB Discovery
      • Macquarie University
      • Macrogenics
      • Mantecorp
      • Mapp Biopharmaceutical
      • Massachusetts General Hospital
      • Mayo Clinic
      • MD Anderson Cancer Center
      • Medical College of Georgia
      • MedImmune
      • Medison Pharma
      • Medivation
      • Melanoma Research Foundation
      • Memorial Sloan Kettering Cancer Center
      • MENTRIK Biotech
      • Mercator Therapeutics
      • Merck and Co
      • Merck KGaA
      • Merck Serono
      • Merck Sharpe & Dohme
      • Merrimack Pharmaceuticals
      • Mersana Therapeutics
      • Merus
      • MicroConstants
      • Micromet
      • Ministry of Health, Labor and Welfare
      • Minomic
      • Mitsubishi Tanabe Pharma
      • Montefiore Medical Center
      • MorphoSys
      • Morphotek
      • Mylan Laboratories
      • Mylan Pharmaceuticals
      • Myriad Genetics
      • NantBioScience
      • NantCell
      • NantKwest
      • NantWorks
      • Nascent Biotech
      • Natco Pharmaceuticals
      • National Cancer Institute
      • National Center for Tumor Diseases
      • National Comprehensive Cancer Network (NCCN)
      • National Institutes of Health
      • NauchTekhStroy Plus
      • Navidea Biopharmaceuticals
      • NCIC Clinical Trials Group
      • Nektar Therapeutics
      • NeoBiotechnologies
      • Neogenix Oncology
      • NeoImmuneTech
      • Neon Therapeutics
      • NeuClone
      • Neuroblastoma and Medulloblastoma Translational Research
      • Newlink Genetics
      • Nexvet
      • NKT Therapeutics
      • Northern Biologics
      • Northwestern University
      • Norwegian Research Council
      • Novartis
      • Novartis Venture Funds
      • Novelogics Biotechnology
      • NovImmune
      • Novo Nordisk
      • Noxxon Pharma
      • Numerate
      • OcellO
      • Oncobiologics
      • OncoImmune
      • OncoMab
      • OncoMax
      • OncoMed Pharmaceuticals
      • OncoQuest
      • OncoSec Medical
      • Oncosynergy
      • Oncothyreon
      • Oncternal Therapeutics
      • Oncurious
      • Ono Pharmaceutical
      • Open Monoclonal Technology
      • OSE Immunotherapeutics
      • Oxford BioTherapeutics
      • OXiGENE
      • Panacea Pharmaceuticals
      • Patrys
      • PDL BioPharma
      • PDS Biotechnology
      • Pelican Therapeutics
      • Peregrine Pharmaceuticals
      • Pfenex
      • Pfizer
      • PharmAbcine
      • Pharmacyclics
      • Pharmanet/i3
      • Philogen
      • Pierre Fabre
      • Pikamab
      • Poseida Therapeutics
      • Precision Antibody
      • Precision Biologics
      • Prestige Brands
      • PRIMA BioMed
      • ProBioGen
      • Progenics Pharmaceuticals
      • Prometheus Laboratories
      • ProtoKinetix
      • Provista Diagnostics
      • PULSALYS
      • QED Bioscience
      • Qualifying Therapeutic Discovery Project
      • Quantum Leap Health Care Collaborative
      • Queensland Institute of Medical Research (QIMR)
      • Quest PharmaTech
      • RayBiotech
      • Recepta Biopharma
      • Regeneron Pharmaceuticals
      • Rentschler Biotechnologie
      • Research Foundation of State University of New York
      • Rexahn Pharmaceuticals
      • Roche
      • Rockefeller University
      • Rockland Immunochemicals
      • Roswell Park Cancer Institute
      • RuiYi
      • SAIC-Frederick
      • Salk Institute
      • Sanford Burnham Institute
      • Sanofi-Aventis
      • Sanofi
      • Sanofi Aventis Korea
      • Sarah Cannon Research Institute
      • SATT Sud-Est
      • Scancell
      • Schrodinger
      • Seattle Genetics
      • Sea Lane Biotechnologies
      • Selexis
      • SELLAS Life Sciences Group
      • Serum Institute of India
      • Servier
      • Shanghai ChemPartner
      • Shanghai Duyiwei Biotech
      • Shenogen Pharma
      • Shire Pharmaceuticals
      • Siena Biotech
      • Sigma-Aldrich
      • Simcere Pharmaceuticals
      • Society of Paediatric Oncology European Neuroblastoma Network (SIOPEN)
      • Sorrento Therapeutics
      • Spectrum Pharmaceuticals
      • Spirogen
      • Stanford University
      • Stason Pharmaceuticals
      • STC Biologics
      • Stem Cell Therapeutics
      • Stonsa Biopharm
      • Structural Genomics
      • Structural Genomics Consortium
      • Surface Oncology
      • Swedish Orphan Biovitrum
      • Symphogen
      • Syndax Pharmaceuticals
      • Synthon
      • Syros Pharmaceuticals
      • Takeda Pharmaceutical
      • Tanabe Research Laboratories
      • Targepeutics
      • Targeted Payload Therapeutics
      • TARIS Biomedical
      • Tasly Pharmaceuticals
      • Telix Pharmaceuticals
      • TeneoBio
      • TenX Biopharma
      • Tesaro
      • Tetragenetics
      • TetraLogic Pharmaceuticals
      • Teva Pharmaceutical Industries
      • TG Therapeutics
      • Theraclone Sciences
      • Theradiag
      • Theranyx
      • The Hospital for Sick Children
      • ThromboGenics
      • Tikcro Technologies
      • Tiziana Life Sciences
      • ToleRx
      • TRACON Pharmaceuticals
      • Transgene
      • Transgene Tasly Biopharmaceutical
      • Transgenomic
      • Trieza Therapeutics
      • TrovaGene
      • TTFactor
      • UCB
      • UMass Memorial Medical Center
      • Universite Claude Bernard Lyon
      • University Health Network
      • University of Alabama at Birmingham
      • University of British Columbia
      • University of California, Davis
      • University of California, San Diego
      • University of California Irvine
      • University of California Los Angeles
      • University of California San Francisco
      • University of Chicago
      • University of Cologne
      • University of Illinois at Chicago
      • University of Massachusetts Medical School
      • University of Minnesota
      • University of North Carolina
      • University of Nottingham
      • University of Pennsylvania
      • University of Pittsburgh
      • University of Toronto
      • University of Wisconsin Carbone Cancer Center (UWCCC)
      • Unum Therapeutics
      • Vaccinex
      • Valneva
      • Valor Biotherapeutics
      • Vaximm
      • Ventana Medical Systems
      • Verastem
      • VIB
      • Viralytics
      • ViroMed
      • Viropro
      • VivaMab
      • VivoPharm
      • VLST Corporation
      • Vyriad
      • Wakunaga Pharmaceuticals
      • Washington University in St Louis
      • Watson Pharmaceuticals
      • Weizmann Institute
      • Wellcome Trust Sanger Institute
      • Wilex
      • X-Body Biosiences
      • XBiotech
      • Xencor
      • Xoma
      • Yale University
      • Yeda Research and Development Company
      • ZAI Laboratory
      • Zenoaq
      • Zenyaku Kogyo
      • Zhejiang Beta Pharma
      • Zhejiang Hisun Pharmaceutical
      • Zhejiang Huahai Pharmaceutical
    • Cancer monoclonal antibody deals by stage of development
      • Discovery
      • Preclinical
      • Phase I
      • Phase II
      • Phase III
      • Regulatory
      • Marketed
      • Formulation
    • Cancer monoclonal antibody deals by deal type
      • Asset purchase
      • Assignment
      • Bigpharma outlicensing
      • Co-development
      • Collaborative R&D
      • Co-market
      • Co-promotion
      • CRADA
      • Development
      • Distribution
      • Equity purchase
      • Evaluation
      • Grant
      • Joint venture
      • Licensing
      • Loan
      • Manufacturing
      • Marketing
      • Material transfer
      • Option
      • Promotion
      • Research
      • Settlement
      • Spin out
      • Sub-license
      • Supply
      • Technology transfer
      • Termination
    • Cancer monoclonal antibody deals by therapy area
      • Oncology
      • Adenocarcinoma
      • Bladder cancer
      • Bone cancer
      • Brain cancer
      • Breast cancer
      • Cervical cancer
      • Colorectal cancer
      • Endometrial
      • Esophageal cancer
      • Gastric cancer
      • Head and neck cancer
      • Kidney cancer
      • Leukemia
      • Acute lymphoblastic leukemia
      • Acute myelogenous leukemia
      • Chronic lymphocytic leukemia
      • Chronic myelogenous leukemia
      • Liver cancer
      • Lung cancer
      • Non small cell lung cancer
      • Small cell lung cancer
      • Lymphoma
      • Hodgkin's lymphoma
      • Non Hodgkin's lymphoma
      • Melanoma
      • Metastases
      • Multiple myeloma
      • Neuroblastoma
      • Ovarian cancer
      • Pancreatic cancer
      • Prostate cancer
      • Renal cell carcinoma
      • Sarcoma
      • Solid tumors
      • Cachexia
      • Cancer pain
      • Thyroid cancer
    • Deal type definitions
  • About Wildwood Ventures
    • Current Partnering
    • Current Agreements
    • Recent report titles from Current Partnering

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report